pJEK6 Alpha-Synuclein E46K Vector
Invented by Dr Fiona Benson from Lancaster University
Invented at Lancaster University
- Datasheet
- References (0)
- Inventor Info
Info
| Catalogue Number | 152051 |
| Relevance |
Alpha synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. Among the familial mutations of α-synuclein in Parkinson′s disease, E46K has the greatest potential to aggregate. |
| Research Area | Neurobiology |
| Notes | pJEK6 ("E46K") is a derivative of pET15b with the open reading frame encoding the E46K mutant human alpha synuclein (α-synuclein) cloned in via the NdeI and BamHI restriction sites. It was constructed via site specific mutagenesis of pJEK1, replacing the G at position 136 in the ORF nucleotide sequence with A, thus altering the 46th codon from GAG encoding Glutamic Acid (E) to AAG encoding Lys (K). In this construct E46K α-synuclein is expressed as a fusion protein with an N-terminal six His tag. |
References
There are 0 reference entries for this reagent.
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
